The goal of the Biospecimens and Patient Registry Core is to provide invesfigators in the Ovarian SPORE high quality pafient data, DNA, RNA, blood products, and cancer fissues from consented pafients with ovarian or primary peritoneal carcinoma and to make these resources available for future studies. The acfivifies of the Core will be conducted in a way that does not compromise patient confidentiality, yet will be as comprehensive as possible in the materials and data that are provided. The acquisifion of human fissue and subsequent cellular/molecular analysis of that fissue coupled with pafient data, maintaining strict confidenfiality, are key to many laboratory-based studies of cancer. The Mayo Clinic has a strong tradition of ethically sound support of research that links fissue acquisifion and patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo's Tissue Registry and the Mayo Archives. Today, the Tissue and Cell Molecular Analysis (TACMA) Shared Resource of the Mayo Clinic Cancer Center is a resource of expertise, collaborafive support, and service for immunohistochemistry, in situ hybridization, tissue microarray construction, and digital imaging. Similarly, the Biospecimens Accessioning and Processing (BAP) Shared Resource is the primary site of accessioning and standardized processing of blood and frozen fissue collected explicitly for research from all three Mayo sites. This Core will be integrated with these existing fissue-oriented Cancer Center shared resources and other scientific Cores of this SPORE to provide 1) a coordinated, centralized, dedicated program for standardized collection, accessioning, processing, morphogenlc classification and evaluafion of biospecimens and 2) pafient data from fully consented ovarian cancer patients. The Core will be closely coordinated with the Biostatistics Core to provide seamless linkage of clinical annotation with research specimens for data management and analyses. Furthermore, under the direcfion of the Administrafion Executive committee and Core, the Biospecimens and Patient Registry Core will make biospecimens collected for this SPORE available to the ovarian cancer research community in order to sfimulate translafional research with the goal of reducing the burden of ovarian cancer.

Public Health Relevance

Biospecimens (tissues and blood) from ovarian cancer pafients and women without cancer are used in research projects designed to improve the detection and treatment of ovarian cancer. This Core supports the collection of these tissues and informafion from the medical record from women who give their written consent to donate these materials for research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Lengyel, Ernst; Litchfield, Lacey M; Mitra, Anirban K et al. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 212:479.e1-479.e10
Earp, Madalene A; Kelemen, Linda E; Magliocco, Anthony M et al. (2014) Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 133:481-97
Liu, Yu-Ping; Wang, Jiahu; Avanzato, Victoria A et al. (2014) Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol 132:722-9
Fridley, Brooke L; Armasu, Sebastian M; Cicek, Mine S et al. (2014) Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. BMC Med Genomics 7:21
Trabert, Britton; Ness, Roberta B; Lo-Ciganic, Wei-Hsuan et al. (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106:djt431
Parker, Peter J; Justilien, Verline; Riou, Philippe et al. (2014) Atypical protein kinase Cýý as a human oncogene and therapeutic target. Biochem Pharmacol 88:1-11
Scott, Clare L; Mackay, Helen J; Haluska Jr, Paul (2014) Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book :e258-66
Charbonneau, Bridget; Moysich, Kirsten B; Kalli, Kimberly R et al. (2014) Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res 2:332-40
Brewer, LaPrincess C; Hayes, Sharonne N; Parker, Monica W et al. (2014) African American women's perceptions and attitudes regarding participation in medical research: the Mayo Clinic/The Links, Incorporated partnership. J Womens Health (Larchmt) 23:681-7
King, Helen; Aleksic, Tamara; Haluska, Paul et al. (2014) Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 40:1096-105

Showing the most recent 10 out of 86 publications